MedTrace Logo

Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma

NCT02341209 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2021-04-27

No results posted yet for this study

Summary

This study looks at the efficacy of Doxycycline for the treatment of Cutaneous T-cell Lymphomas.

Conditions

  • Cutaneous T-cell Lymphoma
  • Mycosis Fungoides
  • Sezary Syndrome

Interventions

DRUG

Doxycycline monohydrate

Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.

Sponsors & Collaborators

  • Rochester General Hospital

    lead OTHER

Principal Investigators

  • Brian Poligone, M.D. Ph.D. · Rochester General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-06
Primary Completion
2021-02-06
Completion
2021-02-06
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02341209 on ClinicalTrials.gov